| 刘魏然,尹化斌.表观遗传学药物FK228抗肿瘤作用的研究进展[J].中国肿瘤,2017,26(6):471-475. |
| 表观遗传学药物FK228抗肿瘤作用的研究进展 |
| Research Progress in Anti-tumor Effect of Histone Deacetylase Inhibitor FK228 |
| 投稿时间：2016-07-08 |
| DOI：10.11735/j.issn.1004-0242.2017.06.A011 |
|
 |
| 中文关键词: FK228 组蛋白去乙酰化酶抑制剂 |
| 英文关键词:FK228 histone deacetylase inhibitor |
| 基金项目:上海市闵行区卫生局自然科学研究课题（2016MHZ331） |
|
| 摘要点击次数: 1992 |
| 全文下载次数: 605 |
| 中文摘要: |
| 摘 要：组蛋白去乙酰化酶抑制剂具有众多生物学功能，如抗肿瘤、抗真菌、抗病毒、抗炎症等作用，其对肿瘤细胞表现出强大的功能。FK228作为一种新型组蛋白去乙酰化酶抑制剂，因其特殊的缩酯环肽结构，可有效透过细胞膜，通过抑制组蛋白去乙酰化酶而显示良好的抗肿瘤活性，同时仅引起轻微的不良反应，已经被美国FDA 批准用于治疗外周及皮肤T-细胞淋巴瘤。全文就FK228在抗肿瘤方面取得的研究进展作一综述。 |
| 英文摘要: |
| Abstract：Histone deacetylase inhibitors possess many biological properties，such as anti-tumor，antifungal，antiviral and anti-inflammatory functions. In particular，the potent effects of histone deacetylase inhibitors on tumor cells have led to researchers focusing on it. As a novel histone deacetylase inhibitor，FK228 has a special cyclic depsipeptide structure，and can pass through cytomembrane to exert an anti-tumor effect；meanwhile it may cause mild adverse reactions. FK228 has been approved by the US Food and Drug Administration (FDA) for treating peripheral and cutaneous T-cell lymphoma. This paper reviews the research progress of FK228 in cancer therapy. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |